New drug cocktail aims to outsmart tough blood cancer

NCT ID NCT04747236

Recruiting now Disease control Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if a combination of two drugs (romidepsin and oral azacytidine) works better than standard single drugs for people with peripheral T-cell lymphoma (PTCL) that has returned or not responded to prior therapy. About 50 adults will be randomly assigned to either the combo or a standard drug chosen by their doctor. The main goal is to see if the combo delays cancer growth longer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PTCL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma peripheral T-cell lymphoma, not otherwise specified

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PTCL

Contacts and locations

Locations

Duke University
RECRUITING

Durham, North Carolina, 27710, United States
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
The Ohio State University
NOT_YET_RECRUITING

Columbus, Ohio, 43210, United States
University of Virginia
RECRUITING

Charlottesville, Virginia, 22911, United States
VA Long Beach Health Care System
RECRUITING

Long Beach, California, 90822, United States
Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.